Trials / Recruiting
RecruitingNCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 218 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCA036978 | INCA036978 will be administered at protocol defined dose. |
| DRUG | Standard disease-directed therapy | A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
Timeline
- Start date
- 2026-04-27
- Primary completion
- 2030-05-24
- Completion
- 2030-05-24
- First posted
- 2026-03-02
- Last updated
- 2026-04-15
Locations
47 sites across 9 countries: United States, Australia, Belgium, Canada, France, Germany, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07441694. Inclusion in this directory is not an endorsement.